Clinical Trial Update: A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy [Phase 3]

View source ↗

Summary

A Phase 3 trial compares maintenance erlotinib versus erlotinib at progression in advanced non-small cell lung cancer after platinum therapy; results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2016-02-29